REFERENCES:

1. Bhagat H.R, Langer R.S., In; Encyclopedia of Pharmaceutical Technology, Swarbrick J., Boylan J.C., Eds., Marcel Dekker. Inc., New York, 1987, (8), 53 –81.
2. Chien Y.W., In; Controlled Drug Delivery: Fundamentals and Application, Robinson J.R., Eds., Marcel Dekker Inc., New York, 1987, 441 –527.
3. Vyas S.P. et al., In; Controlled Drug Delivery, Vallabh Prakashan, Delhi, 1st Edn., 2002, 448 –455.
4. Ansel H.C., Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott Williams and Wilkins, 8th Edn., 2003, 500-501, 668 –670.
5. Eenink M.J.D., Advances of Drug Delivery Systems, Elsevier, Amsterdam, 1987, 3, 225.
6. Chakraborty P., In; Practical Pathology, New Central Book Agency Pvt. Ltd., Calcutta, 1st Edn., 1998, 258–259.
7. Robbins S.L., In; Basic Pathology, Saunders Publication, 7th Edn., 2003, 761–763.
8. Sivanet M.,Osteomyelitis and septic arthritis,Joint Bone Spine, 2008, 20, 1–3.
9. Tanaka K. ,Osteomyelitis,Bioorganic Med. Chem., 2008, 15, 34.
10. Werner Z., M.D., Andrej Trampuz, M.D., and Peter E. Ochsner, M.D.,Prosthetic-Joint Infections,N. Engl. J. Med., 2004, 351, 1645 –1654.
11. Luca L. MD, Jon t. Mader, MD, and Jason H. Calhoun md, Osteomyelitis in Long Bones,J. Bone Joint Surg., 2004, 86, 2305 –2318.
12. Lazzarini L, Mader JT, Calhoun JH., Osteomyelitis in long bones. J Bone Joint Surg Am 2004; 86-A: 2305e18.
13. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9: 127e38
14. http:// www. ummc. com./
15. Monzon M.,Felícito G, Antonio L and Beatriz A.,Evaluation of four experimental osteomyelitis infection models by using precolonized implants and bacterial suspensions,Acta Orthopedica, 2002,73 (1), 11–19.
16. Takahashi M.,Development of implant tablet for a week-long sustained release, J. Control. Release., 2004, 63 –74.

17. Castro C.,E. Sa´ncheza, A. Delgadoa, I. Soriano.,Ciprofloxacin implants for bone infection. In vitro–in vivo characterization, J. Controlled Release, 2003, 93, 341– 354.
18. Cyril D., Pascal D, Vincent L., Characterization of crosslinked high amylose starch matrix implants 1. In vitro release of ciprofloxacin, J. Control. Release., 2002, 82, 83–93.
19. Cyril D., Pascal D, Vincent L., Characterization of crosslinked high amylose starch matrix implants 2. In vivo release of ciprofloxacinJ. Control. Release., 2002, 82, 95–103.
20. Koort J., et al., Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant, Acta Orthopaedica, 2008, 79(2), 295–301.
21. Evora C. M., Baroc, I., Sorianoa, E. Sa´ncheza.,Two-month ciprofloxacin implants for multibacterial bone infections, Eur. J. Pharm. Biopharm., 2005, 60, 401–406.
22. Ramchandani M., Robinson D., In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants, J. Control. Release., 1998, 54(2), 167 – 175.
23 Baro M. E. Sa´nchezb, A. Delgadob, A. Pererac,, In vitro–in vivo characterization of gentamicin bone implants, J. Control. Release., 2002, 353–364.
24 Prabhaharan M., Mano J. F., Chitosan-based particles as controlled drug delivery systems, Drug Del., 2005., 12, 41–57.
25 Samit K. Nandi , Cefuroxime-impregnated calcium phosphates as an implantable delivery system in experimental osteomyelitis, Ceramics International ,2009, 35, 1367–1376.
26. Shah J., Saleh A., United States Patent, 5891456, 1999.
27. Genin F., Dash K., United States Patent, 6767550, 2004.
28. Runkel A., Jung Shung Lee., United States Patent, 5035891,1991.
29. Lenaerts V., Ronald H., Elsie V., United States Patent, 6607748, 2003.
30. Wong V., Mae W.,United States Patent, 6331313, 2001.
31. Peih-Jeng Jiang, Sarika Patel, Uwe Gbureck,Comparing the Efficacy of Three Bioceramic Matrices for theRelease of Vancomycin Hydrochloride, Journal of Biomedical Materials Research Part B,2009, 51-56.
32. Nayak A. K.*, Bhattacharya A. and Sen K. K., Hydroxyapatite-antibiotic implantable minipellets for bacterial bone infections using precipitation technique, Journal of Pharmacy Research 2010, 3(1),53-59.
33. T.H. Hoang., Thia,, F. Chai., Bone implants modified with cyclodextrin: Study of drug

release in bulk fluid and into agarose gel, Int J. ofPharmaceutics,400 (2010) 74–85.
34. F. Kreyea,b, F. Siepmanna, Drug release mechanisms of compressed lipid implants, Int J. of Pharmaceutics,2011,404, 27–35.
35. M.P. Ginebra, T. Traykova, Calcium phosphate cements as bone drug delivery systems: A review, Journal of Controlled Release, 2006, 113 , 102–110.
36. Amal H. El-Kamel, Manal M. Baddour, Gatifloxacin Biodegradable Implant for Treatment of Experimental Osteomyelitis: In Vitro and In Vivo Evaluation, Drug Delivery, 14:1–8, 2007.
37. Taufeeq A..,Development of Gentamicin Biodegradable Implant, Saudi Pharm. J., 2006, 14(2), 120–125.
38. Catherine G. A. et al., Clinical Orthopedics and Related Research, 2004, No. 421, 293–299.
39. Emmanuel A., Vessela V.,*In vitroIn vivo* characterization of a novel biocompatible polymer lipid implant system for the sustained delivery of paclitaxel. , J. Control. Release., 2005, 104, 181 –191.
40. Anand A., Pundir R., Cefaperazone impreganated polycaprolactone implant, Ind. J.Pharm.Sci.,2009, 347-342.
41. Hauo Ru Zhao., Deirdre O. C., Implant of extract of danshen (Radix Salviae, miltiorrhizae),Eur. J. Pharm. Biopharm., 2006, 62, 295–305.
42. Saraswathy G. et al., Novel bio inorganic bone implant containing deglued bone, chitosan and gelatin, Bull. Mater. Sci., 2005, 24 (4), 415 – 420.